HSBC has downgraded AbbVie Inc (ABBV) to Hold from Buy, a move that underscores growing caution regarding the company's future performance. As of September 30, 2025, AbbVie shares are priced at $235.48.
This revision may reflect concerns about competitive pressures, market conditions, or execution risks that could impact AbbVie’s operations. With a market capitalization of $411.6 billion, AbbVie is a major player in the biotechnology industry, engaging in the development and sale of pharmaceutical products. The company, headquartered in North Chicago, Illinois, employs 55,000 full-time staff and has a diverse product portfolio that includes offerings in immunology, oncology, aesthetics, neuroscience, and eye care.
Analyst ratings and price targets serve as professional opinions based on research and financial models. While these assessments can provide valuable insights, they are based on assumptions that may not always materialize. Therefore, investment decisions should take into account a variety of factors, including company fundamentals, competitive positioning, and industry trends. Analyst views should be one of many inputs rather than the sole basis for investment choices.
The downgrade comes amid a mixed analyst consensus, which as of November 1, 2025, includes 9 Strong Buy, 17 Buy, and 11 Hold ratings. Recent earnings reports also show AbbVie’s performance has been largely in line with expectations, with a Q3 2025 EPS of $1.86 surpassing estimates by 2.7%. Upcoming earnings are scheduled for July 29, 2026, with an EPS estimate of $3.71 and revenue expected to reach $17.0 billion.
Analyst ratings can evolve as new information becomes available, and differing opinions on the same company are common among analysts.